![]() (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®. The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. Follow-up with patients in this trial is ongoing.ĭisclosure: For full disclosures of the study authors, visit . Bristol Myers Squibb (NYSE: BMY) today announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo (nivolumab) for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma. Galsky and colleagues in The New England Journal of Medicine. CheckMate 274 (NCT02632409), a phase 3 trial of adjuvant nivolumab (NIVO) vs placebo (PBO) in high-risk muscle-invasive urothelial carcinoma (MIUC) after radical resection, demonstrated improved disease-free survival (DFS) with adjuvant NIVO vs PBO in the intent-to-treat (ITT) and tumor PD-L1 expression 1 populations. These longer-term disease-free survival data presented at the American Urology Association Annual Meeting built upon initial data presented by Dr. Patients with PD-L1–positive tumors had cancer-free rates that were even higher. The double-blind CheckMate 274 trial randomly assigned patients 1:1 to receive either nivolumab 240 mg twice weekly or placebo for a total adjuvant treatment time of 1 year or until disease. In CheckMate 274, with a minimum of 11 months’ follow-up, patients who received nivolumab had an approximately 30% lower likelihood of developing cancer recurrence than those who received placebo. Unfortunately for these patients, no consensus has emerged regarding treatments after surgery that might reduce the risk of cancer recurrence. Ohne Gewhr fr Richtigkeit oder Vollstndigkeit. Surgery that removes the bladder or kidney and ureter has been the standard of care for patients with urothelial cancer that has entered surrounding muscle or lymph nodes, but approximately half of these patients later relapse. Clinical Trial Center Network (CTCN) Zentrale am Universittsklinikum Frankfurt. “Almost 200,000 people die each year of urothelial cancer worldwide, so advances like immunotherapy being used in this manner bring hope.” Checkmate 274 Do you think adjuvant nivolumab should be the new standard of care based on current CM274 DFS data If OS turns out to be no different, will. Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma Indian J Urol. ![]() ![]() Galsky, Director of Genitourinary Medical Oncology at Mount Sinai Tisch Cancer Center. “Longer-term follow-up data are important for reinforcing the initial results we published last year demonstrating for the first time that immunotherapy administered after surgery for bladder cancer and other urothelial cancer can decrease the risk of cancer recurrence,” said Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |